SAMH
ANAB icon

Shanda Asset Management Holdings’s AnaptysBio ANAB Stock Holding History

Shanda Asset Management Holdings’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-20,039
Closed -$448K – 54
2020
Q2 		$448K Buy
+20,039
New +$366K 0.04% 81

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Shanda Asset Management Holdings's ANAB Position: Q3 2020 in Review

Shanda Asset Management Holdings sold out of AnaptysBio (ANAB) in Q3 2020, closing a stake of 20,039 shares — an estimated $448K sold.

Shanda Asset Management Holdings first reported a position in ANAB in Q2 2020 and held it in 1 quarter. The position peaked at $448K in Q2 2020. 132 funds tracked by Wall St. Rank hold ANAB as of Q3 2020.

  • Shanda Asset Management Holdings reported no remaining AnaptysBio position as of Q3 2020 after selling out during the quarter.
  • Shanda Asset Management Holdings sold 20,039 AnaptysBio shares in Q3 2020, an estimated $448K.
  • Shanda Asset Management Holdings first reported a position in AnaptysBio in Q2 2020 and held it in 1 quarter.
  • Shanda Asset Management Holdings's AnaptysBio position peaked at $448K in Q2 2020.
  • 132 funds tracked by Wall St. Rank held AnaptysBio as of Q3 2020.

Based on Shanda Asset Management Holdings's 13F filing for Q3 2020, filed 16 Nov 2020.